|Day Low/High||2.01 / 2.23|
|52 Wk Low/High||1.08 / 3.33|
The patent extends the Company's coverage to areas of future clinical investigation in diseases associated with elevations in iNOS
Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial
13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis
In recent trading, shares of Galectin Therapeutics Inc have crossed above the average analyst 12-month target price of $2.08, changing hands for $2.30/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Investors in Galectin Therapeutics Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALT options chain for the new May 19th contracts and identified the following put contract of particular interest.
First-in-human data presented at GTCBio 9th Immunotherapeutics & Immunomonitoring Conference
Common and Preferred private placements completed at above market prices
Meaningful activity of GR-MD-02 in treating psoriasis and preliminary data in treating atopic dermatitis suggests promise in treatment of serious skin disease
Research to be presented at The Liver Meeting® 2016 demonstrates correlation of FibroScan and MRE as non-invasive tests to assess the progression of liver fibrosis and cirrhosis
H.C. Wainwright reduced Galectin Thereapeutics' (GALT) stock rating to 'neutral' after the company's fatty liver disease drug failed in a phase II clinical trial.
Galectin Therapeutics' (GALT) stock rating was cut two notches to 'sell' at Roth Capital on Wednesday after the company's drug for fatty liver disease failed a clinical trial.